PERK-eIF2alpha-mediated translational inhibition of MCL-1 contributes to potential 2-deoxy-D-glucose and BAD mimetic...

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Biology

Background:

• Tumors rely heavily on aerobic glycolysis for energy.
• 2-Deoxy-D-glucose (2DG) is a glycolysis inhibitor studied for cancer therapy.
• The exact mechanism of 2DG's toxicity is not fully understood.

Purpose of the Study:

• To elucidate the precise mechanism of 2DG-induced apoptosis.
• To investigate the role of glycosylation, glycolysis, and specific proteins in 2DG toxicity.
• To explore the potential of combining 2DG with BH3 mimetics for cancer treatment.

Main Methods:

• Assessing 2DG's impact on apoptosis and protein levels (MCL-1, BAD).
• Utilizing gene knockout strategies to identify key apoptotic regulators.
• Investigating the involvement of Endoplasmic Reticulum (ER) stress and the PERK-eIF2α pathway.
• Evaluating the efficacy of combined 2DG and BAD BH3 mimetic treatment.

Main Results:

• 2DG induces apoptosis primarily by disrupting glycosylation, leading to MCL-1 protein reduction.
• 2DG toxicity is dependent on MCL-1 degradation and BAD dephosphorylation.
• The PERK-eIF2α pathway mediates translational inhibition of MCL-1, contributing to 2DG toxicity.
• Combined 2DG and BAD BH3 mimetic treatment effectively targets various cancer cells.

Conclusions:

• 2DG toxicity is mediated by disrupted glycosylation and subsequent protein degradation, not solely glycolysis inhibition.
• MCL-1 downregulation and BAD dephosphorylation are critical events in 2DG-induced apoptosis.
• ER stress-induced translational inhibition of MCL-1 contributes to 2DG's anti-cancer effects.
• Combining 2DG with BH3 mimetics presents a viable and promising therapeutic strategy for cancer treatment.